

# Craig W Lindsley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7261207/publications.pdf>

Version: 2024-02-01

633  
papers

18,889  
citations

16791

66  
h-index

25983

112  
g-index

659  
all docs

659  
docs citations

659  
times ranked

17381  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. <i>British Journal of Ophthalmology</i> , 2022, 106, 288-296.	2.1	11
2	Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 56, 128479.	1.0	1
3	The effects of predator odor (TMT) exposure and mGlu3 NAM pretreatment on behavioral and NMDA receptor adaptations in the brain. <i>Neuropharmacology</i> , 2022, 207, 108943.	2.0	9
4	A Call for Diversity Story Guest Editorials. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1609-1609.	2.9	1
5	Acute restraint stress redirects prefrontal cortex circuit function through mGlu5 receptor plasticity on somatostatin-expressing interneurons. <i>Neuron</i> , 2022, 110, 1068-1083.e5.	3.8	36
6	Effects of acute and repeated administration of the selective M <sub>4</sub> PAM VU0152099 on cocaine versus food choice in male rats. <i>Addiction Biology</i> , 2022, 27, e13145.	1.4	5
7	<i>Journal of Medicinal Chemistry</i> / <i>ACS Medicinal Chemistry Letters</i> /Division of Medicinal Chemistry Joint Portuguese Lectureship Awards: <b>CALL FOR NOMINATIONS</b> . <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1610-1611.	2.9	3
8	A Virtual Collection Focused on Antifungal Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2022, , .	2.9	1
9	A Virtual Collection Focused on Antifungal Drug Discovery. <i>ACS Infectious Diseases</i> , 2022, , .	1.8	0
10	A Virtual Collection Focused on Antifungal Drug Discovery. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 327.	1.3	0
11	2022: Celebrating the 65th Publication Volume of the <i>Journal of Medicinal Chemistry</i> . <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1-1.	2.9	0
12	Development of <b>VU6019650</b> : A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M <sub>5</sub> Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6273-6286.	2.9	8
13	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors”€What Is Expected?. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6973-6974.	2.9	10
14	mGlu1-mediated restoration of prefrontal cortex inhibitory signaling reverses social and cognitive deficits in an NMDA hypofunction model in mice. <i>Neuropsychopharmacology</i> , 2022, 47, 1826-1835.	2.8	4
15	Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome. <i>Neurotherapeutics</i> , 2022, 19, 1340-1352.	2.1	3
16	Optimized Administration of the M <sub>4</sub> PAM VU0467154 Demonstrates Broad Efficacy, but Limited Effective Concentrations in <i>Mecp2</i> <sup>+/+</sup> Mice. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1891-1901.	1.7	0
17	Confronting Racism in Chemistry Journals. <i>ACS ES&amp;T Engineering</i> , 2021, 1, 3-5.	3.7	0
18	Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 4: SAR reveals positive cooperativity across multiple mGlu receptor subtypes leading to subtype unselective PAMs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 32, 127724.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Confronting Racism in Chemistry Journals. ACS ES&T Water, 2021, 1, 3-5.	2.3	0
20	The Philip S. Portoghese <i>Journal of Medicinal</i> <i>Chemistry</i>/Division of Medicinal Chemistry Joint Lectureship Awards. Journal of Medicinal Chemistry, 2021, 64, 2311-2311.	2.9	2
21	Ten-Year Retrospective of the Vanderbilt Institute of Chemical Biology Chemical Synthesis Core. ACS Chemical Biology, 2021, 16, 787-793.	1.6	0
22	Discovery and optimization of a novel CNS penetrant series of mGlu4 PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model. Bioorganic and Medicinal Chemistry Letters, 2021, 37, 127838.	1.0	3
23	Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu <sub>2</sub> /mGlu <sub>4</sub> receptor heterodimers. Science Signaling, 2021, 14, .	1.6	14
24	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. ACS Medicinal Chemistry Letters, 2021, 12, 669-669.	1.3	0
25	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. Journal of Medicinal Chemistry, 2021, 64, 5225-5225.	2.9	2
26	Giving Credit Where Credit Is Due: Properly Citing Relevant Prior Art. ACS Chemical Neuroscience, 2021, 12, 1465-1465.	1.7	0
27	Muscarinic M<sub>4</sub> and M<sub>5</sub> receptors in the ventral subiculum differentially modulate alcohol seeking versus consumption in male alcoholâ€preferring rats. British Journal of Pharmacology, 2021, 178, 3730-3746.	2.7	9
28	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	2.9	0
29	Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG. Frontiers in Neuroscience, 2021, 15, 700822.	1.4	5
30	Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic Efficacy. ACS Pharmacology and Translational Science, 2021, 4, 1306-1321.	2.5	11
31	Identification of a Novel Allosteric Site at the M5 Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2021, 12, 3112-3123.	1.7	6
32	DARK Classics in Chemical Neuroscience: Loperamide. ACS Chemical Neuroscience, 2021, 12, 2964-2973.	1.7	2
33	Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist. ACS Medicinal Chemistry Letters, 2021, 12, 1342-1349.	1.3	6
34	Discovery of â€Molecular Switchesâ€within a Series of mGlu<sub>5</sub> Allosteric Ligands Driven by a â€Magic Methylâ€Effect Affording Both PAMs and NAMs with <i>In Vivo</i> Activity, Derived from an M<sub>1</sub> PAM Chemotype. ACS Bio & Med Chem Au, 2021, 1, 21-30.	1.7	3
35	Activating mGlu3 Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus. Biological Psychiatry, 2021, 90, 385-398.	0.7	27
36	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i>, <i>ACS Medicinal Chemistry Letters</i>, and <i>ACS Pharmacology & Translational Science</i>. Journal of Medicinal Chemistry, 2021, 64, 13935-13936.	2.9	3

#	ARTICLE	IF	CITATIONS
37	Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 47, 128193.	1.0	2
38	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i> , <i>ACS Medicinal Chemistry Letters</i> , and <i>ACS Pharmacology &amp; Translational Science</i> . <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1508-1509.	1.3	2
39	New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by <i>Journal of Medicinal Chemistry</i> , <i>ACS Medicinal Chemistry Letters</i> , and <i>ACS Pharmacology &amp; Translational Science</i> . <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1712-1713.	2.5	0
40	Positive allosteric modulators (PAMs) of the group II metabotropic glutamate receptors: Design, synthesis, and evaluation as ex-vivo tool compounds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 50, 128342.	1.0	2
41	2021: A New Year and New Directions for the <i>Journal of Medicinal Chemistry</i> . <i>Journal of Medicinal Chemistry</i> , 2021, 64, 1-1.	2.9	2
42	Development of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes - Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 53, 128416.	1.0	0
43	mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits. <i>Cell Reports</i> , 2021, 37, 109950.	2.9	21
44	Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model. , 2021, 62, 8.		8
45	Age and circadian rhythmâ€dependent effects of M <sub>1</sub> muscarinic acetylcholine receptor positive allosteric modulators and donepezil on sleepâ€wake architecture and arousal. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
46	Discovery and Optimization of a Novel Series of Competitive and Central Nervous System-Penetrant Protease-Activated Receptor 4 (PAR4) Inhibitors. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4524-4534.	1.7	2
47	Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators. <i>Molecular Psychiatry</i> , 2020, 25, 2786-2799.	4.1	28
48	DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB). <i>ACS Chemical Neuroscience</i> , 2020, 11, 3850-3859.	1.7	14
49	Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126811.	1.0	3
50	Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126812.	1.0	2
51	mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects. <i>Neuron</i> , 2020, 105, 46-59.e3.	3.8	56
52	RedH and PigC Catalyze the Biosynthesis of Hybrubins via Phosphorylation of 4â€Methoxy-2,2â€Bipyrrole-5â€Carbaldehyde. <i>Applied and Environmental Microbiology</i> , 2020, 86, .	1.4	1
53	Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 29-33.	1.3	20
54	Synthesis and SAR of a series of mGlu7 NAMs based on an ethyl-8-methoxy-4-(4-phenylpiperazin-1-yl)quinoline carboxylate core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127529.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Confronting Racism in Chemistry Journals. ACS Pharmacology and Translational Science, 2020, 3, 559-561.	2.5	0
56	Confronting Racism in Chemistry Journals. Biochemistry, 2020, 59, 2313-2315.	1.2	0
57	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Biomaterials Science and Engineering, 2020, 6, 2707-2708.	2.6	0
58	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Central Science, 2020, 6, 589-590.	5.3	0
59	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Chemical Biology, 2020, 15, 1282-1283.	1.6	0
60	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Chemical Neuroscience, 2020, 11, 1196-1197.	1.7	0
61	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Earth and Space Chemistry, 2020, 4, 672-673.	1.2	0
62	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Energy Letters, 2020, 5, 1610-1611.	8.8	1
63	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Macro Letters, 2020, 9, 666-667.	2.3	0
64	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. , 2020, 2, 563-564.		0
65	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Nano, 2020, 14, 5151-5152.	7.3	2
66	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Photonics, 2020, 7, 1080-1081.	3.2	0
67	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Pharmacology and Translational Science, 2020, 3, 455-456.	2.5	0
68	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Sustainable Chemistry and Engineering, 2020, 8, 6574-6575.	3.2	0
69	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Analytical Chemistry, 2020, 92, 6187-6188.	3.2	0
70	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Chemistry of Materials, 2020, 32, 3678-3679.	3.2	0
71	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Environmental Science and Technology Letters, 2020, 7, 280-281.	3.9	1
72	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical Education, 2020, 97, 1217-1218.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Proteome Research, 2020, 19, 1883-1884.	1.8	0
74	Confronting Racism in Chemistry Journals. Langmuir, 2020, 36, 7155-7157.	1.6	0
75	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Polymer Materials, 2020, 2, 1739-1740.	2.0	0
76	NeuroChat with Dr. Karen Gregory. ACS Chemical Neuroscience, 2020, 11, 1373-1375.	1.7	0
77	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Combinatorial Science, 2020, 22, 223-224.	3.8	0
78	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Medicinal Chemistry Letters, 2020, 11, 1060-1061.	1.3	0
79	Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127418.	1.0	6
80	Welcome BACK to the DARK Side: DARK Classics in Chemical Neuroscience II. ACS Chemical Neuroscience, 2020, 11, 3849-3849.	1.7	0
81	Editorial Confronting Racism in Chemistry Journals. , 2020, 2, 829-831.		0
82	ACS Pharmacology & Translational Science, Version 2.0. ACS Pharmacology and Translational Science, 2020, 3, 562-562.	2.5	0
83	Restoring Agonist Function at a Chemogenetically Modified M <sub>1</sub> Muscarinic Acetylcholine Receptor. ACS Chemical Neuroscience, 2020, 11, 4270-4279.	1.7	1
84	DARK Classics in Chemical Neuroscience: Carfentanil. ACS Chemical Neuroscience, 2020, 11, 3955-3967.	1.7	18
85	Welcome to Professor Hsin-Yi Lai, the Newest Associate Editor for ACS Chemical Neuroscience. ACS Chemical Neuroscience, 2020, 11, 1519-1519.	1.7	0
86	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry Letters, 2020, 11, 5279-5281.	2.1	1
87	Confronting Racism in Chemistry Journals. ACS Applied Energy Materials, 2020, 3, 6016-6018.	2.5	0
88	Confronting Racism in Chemistry Journals. ACS Central Science, 2020, 6, 1012-1014.	5.3	1
89	Confronting Racism in Chemistry Journals. Industrial & Engineering Chemistry Research, 2020, 59, 11915-11917.	1.8	0
90	NeuroChat with Research Assistant Professor Alison Axtman. ACS Chemical Neuroscience, 2020, 11, 2783-2785.	1.7	0

#	ARTICLE	IF	CITATIONS
91	Confronting Racism in Chemistry Journals. <i>Journal of Natural Products</i> , 2020, 83, 2057-2059.	1.5	0
92	Confronting Racism in Chemistry Journals. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1354-1356.	1.3	0
93	Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates. <i>Neuropsychopharmacology</i> , 2020, 45, 2219-2228.	2.8	13
94	Confronting Racism in Chemistry Journals. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 1321-1323.	1.2	1
95	Confronting Racism in Chemistry Journals. <i>Energy &amp; Fuels</i> , 2020, 34, 7771-7773.	2.5	0
96	Confronting Racism in Chemistry Journals. <i>ACS Sensors</i> , 2020, 5, 1858-1860.	4.0	0
97	Confronting Racism in Chemistry Journals. <i>ACS Nano</i> , 2020, 14, 7675-7677.	7.3	2
98	CNS Pathogens: A Special Issue of <i>ACS Chemical Neuroscience</i> . <i>ACS Chemical Neuroscience</i> , 2020, 11, 2370-2370.	1.7	0
99	Discovery of VU6027459: A First-in-Class Selective and CNS Penetrant mGlu <sub>7</sub> Positive Allosteric Modulator Tool Compound. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1773-1779.	1.3	8
100	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>Biochemistry</i> , 2020, 59, 1641-1642.	1.2	0
101	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>Journal of Chemical &amp; Engineering Data</i> , 2020, 65, 2253-2254.	1.0	0
102	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>Organic Process Research and Development</i> , 2020, 24, 872-873.	1.3	0
103	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Omega</i> , 2020, 5, 9624-9625.	1.6	0
104	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Applied Electronic Materials</i> , 2020, 2, 1184-1185.	2.0	0
105	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 20147-20148.	4.0	5
106	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>Journal of Physical Chemistry C</i> , 2020, 124, 9629-9630.	1.5	0
107	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 3571-3572.	2.1	0
108	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. <i>ACS Synthetic Biology</i> , 2020, 9, 979-980.	1.9	0

#	ARTICLE	IF	CITATIONS
109	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Energy Materials, 2020, 3, 4091-4092.	2.5	0
110	Confronting Racism in Chemistry Journals. Journal of Chemical Theory and Computation, 2020, 16, 4003-4005.	2.3	0
111	Confronting Racism in Chemistry Journals. Journal of Organic Chemistry, 2020, 85, 8297-8299.	1.7	0
112	Confronting Racism in Chemistry Journals. Analytical Chemistry, 2020, 92, 8625-8627.	3.2	0
113	Confronting Racism in Chemistry Journals. Journal of Chemical Education, 2020, 97, 1695-1697.	1.1	0
114	Confronting Racism in Chemistry Journals. Organic Process Research and Development, 2020, 24, 1215-1217.	1.3	0
115	Confronting Racism in Chemistry Journals. ACS Sustainable Chemistry and Engineering, 2020, 8, .	3.2	0
116	Confronting Racism in Chemistry Journals. Chemistry of Materials, 2020, 32, 5369-5371.	3.2	0
117	Confronting Racism in Chemistry Journals. Chemical Research in Toxicology, 2020, 33, 1511-1513.	1.7	0
118	Confronting Racism in Chemistry Journals. Inorganic Chemistry, 2020, 59, 8639-8641.	1.9	0
119	Confronting Racism in Chemistry Journals. ACS Applied Nano Materials, 2020, 3, 6131-6133.	2.4	0
120	Confronting Racism in Chemistry Journals. ACS Applied Polymer Materials, 2020, 2, 2496-2498.	2.0	0
121	Confronting Racism in Chemistry Journals. ACS Chemical Biology, 2020, 15, 1719-1721.	1.6	0
122	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical Theory and Computation, 2020, 16, 2881-2882.	2.3	0
123	Confronting Racism in Chemistry Journals. Organic Letters, 2020, 22, 4919-4921.	2.4	4
124	Confronting Racism in Chemistry Journals. ACS Applied Materials & Interfaces, 2020, 12, 28925-28927.	4.0	13
125	Confronting Racism in Chemistry Journals. Crystal Growth and Design, 2020, 20, 4201-4203.	1.4	1
126	Confronting Racism in Chemistry Journals. Chemical Reviews, 2020, 120, 5795-5797.	23.0	2



#	ARTICLE	IF	CITATIONS
127	Confronting Racism in Chemistry Journals. ACS Catalysis, 2020, 10, 7307-7309.	5.5	1
128	Confronting Racism in Chemistry Journals. Biomacromolecules, 2020, 21, 2543-2545.	2.6	0
129	Confronting Racism in Chemistry Journals. Journal of Medicinal Chemistry, 2020, 63, 6575-6577.	2.9	0
130	Confronting Racism in Chemistry Journals. Macromolecules, 2020, 53, 5015-5017.	2.2	0
131	Confronting Racism in Chemistry Journals. Nano Letters, 2020, 20, 4715-4717.	4.5	5
132	Confronting Racism in Chemistry Journals. Organometallics, 2020, 39, 2331-2333.	1.1	0
133	Confronting Racism in Chemistry Journals. Journal of the American Chemical Society, 2020, 142, 11319-11321.	6.6	1
134	Phenotypic profiling of <i>mGlu7</i> knockout mice reveals new implications for neurodevelopmental disorders. Genes, Brain and Behavior, 2020, 19, e12654.	1.1	25
135	Chronic Traumatic Encephalopathy (CTE): A Virtual Issue Dedicated to Advances in Understanding, Diagnosing, and Potentially Treating Tauopathies. ACS Chemical Neuroscience, 2020, 11, 994-994.	1.7	1
136	Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. Biological Psychiatry, 2020, 88, 898-909.	0.7	24
137	Confronting Racism in Chemistry Journals. Accounts of Chemical Research, 2020, 53, 1257-1259.	7.6	0
138	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry A, 2020, 124, 5271-5273.	1.1	0
139	Confronting Racism in Chemistry Journals. ACS Energy Letters, 2020, 5, 2291-2293.	8.8	0
140	Confronting Racism in Chemistry Journals. Journal of Chemical Information and Modeling, 2020, 60, 3325-3327.	2.5	0
141	Confronting Racism in Chemistry Journals. Journal of Proteome Research, 2020, 19, 2911-2913.	1.8	0
142	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry B, 2020, 124, 5335-5337.	1.2	1
143	<b>DARK</b> Classics in Chemical Neuroscience: U-47700. ACS Chemical Neuroscience, 2020, 11, 3928-3936.	1.7	15
144	Update to Our Reader, Reviewer, and Author Communities—April 2020. Journal of Agricultural and Food Chemistry, 2020, 68, 5019-5020.	2.4	0

#	ARTICLE	IF	CITATIONS
145	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Physical Chemistry B, 2020, 124, 3603-3604.	1.2	0
146	Confronting Racism in Chemistry Journals. Bioconjugate Chemistry, 2020, 31, 1693-1695.	1.8	0
147	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Nano Materials, 2020, 3, 3960-3961.	2.4	0
148	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Natural Products, 2020, 83, 1357-1358.	1.5	0
149	Confronting Racism in Chemistry Journals. ACS Synthetic Biology, 2020, 9, 1487-1489.	1.9	0
150	Confronting Racism in Chemistry Journals. Journal of Chemical & Engineering Data, 2020, 65, 3403-3405.	1.0	0
151	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Bioconjugate Chemistry, 2020, 31, 1211-1212.	1.8	0
152	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical Health and Safety, 2020, 27, 133-134.	1.1	0
153	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Chemical Research in Toxicology, 2020, 33, 1509-1510.	1.7	0
154	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Energy & Fuels, 2020, 34, 5107-5108.	2.5	0
155	2020â€™ A Year of Growth for ACS Chemical Neuroscience. ACS Chemical Neuroscience, 2020, 11, 225-225.	1.7	0
156	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Applied Bio Materials, 2020, 3, 2873-2874.	2.3	0
157	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Organic Chemistry, 2020, 85, 5751-5752.	1.7	0
158	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of the American Society for Mass Spectrometry, 2020, 31, 1006-1007.	1.2	0
159	Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats. Neuropharmacology, 2020, 171, 108089.	2.0	15
160	Synthesis of Substituted 6,7-Dihydro-5 <i>H</i> -pyrrolo[2,3- <i>c</i> ]pyridazines/pyrazines via Catalyst-Free Tandem Hydroaminationâ€™ Aromatic Substitution. Journal of Organic Chemistry, 2020, 85, 6123-6130.	1.7	6
161	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Accounts of Chemical Research, 2020, 53, 1001-1002.	7.6	0
162	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Biomacromolecules, 2020, 21, 1966-1967.	2.6	0

#	ARTICLE	IF	CITATIONS
163	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Chemical Reviews, 2020, 120, 3939-3940.	23.0	0
164	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Environmental Science & Technology, 2020, 54, 5307-5308.	4.6	0
165	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Langmuir, 2020, 36, 4565-4566.	1.6	0
166	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Molecular Pharmaceutics, 2020, 17, 1445-1446.	2.3	0
167	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Infectious Diseases, 2020, 6, 891-892.	1.8	0
168	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Crystal Growth and Design, 2020, 20, 2817-2818.	1.4	1
169	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Medicinal Chemistry, 2020, 63, 4409-4410.	2.9	0
170	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Physical Chemistry A, 2020, 124, 3501-3502.	1.1	0
171	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Nano Letters, 2020, 20, 2935-2936.	4.5	0
172	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. ACS Sensors, 2020, 5, 1251-1252.	4.0	0
173	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of Chemical Information and Modeling, 2020, 60, 2651-2652.	2.5	0
174	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Industrial & Engineering Chemistry Research, 2020, 59, 8509-8510.	1.8	0
175	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Journal of the American Chemical Society, 2020, 142, 8059-8060.	6.6	3
176	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Inorganic Chemistry, 2020, 59, 5796-5797.	1.9	0
177	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Organometallics, 2020, 39, 1665-1666.	1.1	0
178	Update to Our Reader, Reviewer, and Author Communitiesâ€™ April 2020. Organic Letters, 2020, 22, 3307-3308.	2.4	0
179	Synthesis and pharmacological evaluation of bivalent tethered ligands to target the mGlu2/4 heterodimeric receptor results in a compound with mGlu2/2 homodimer selectivity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127212.	1.0	3
180	Confronting Racism in Chemistry Journals. ACS Biomaterials Science and Engineering, 2020, 6, 3690-3692.	2.6	1

#	ARTICLE	IF	CITATIONS
181	Classics in Chemical Neuroscience: Baclofen. ACS Chemical Neuroscience, 2020, 11, 1740-1755.	1.7	43
182	Confronting Racism in Chemistry Journals. ACS Omega, 2020, 5, 14857-14859.	1.6	1
183	The Effects of the M 1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0486846 on Cognitive Performance in Aged Nonhuman Primates. FASEB Journal, 2020, 34, 1-1.	0.2	0
184	Confronting Racism in Chemistry Journals. ACS Applied Electronic Materials, 2020, 2, 1774-1776.	2.0	0
185	Confronting Racism in Chemistry Journals. Journal of Agricultural and Food Chemistry, 2020, 68, 6941-6943.	2.4	0
186	Confronting Racism in Chemistry Journals. ACS Earth and Space Chemistry, 2020, 4, 961-963.	1.2	0
187	Confronting Racism in Chemistry Journals. Environmental Science and Technology Letters, 2020, 7, 447-449.	3.9	0
188	Confronting Racism in Chemistry Journals. ACS Combinatorial Science, 2020, 22, 327-329.	3.8	0
189	Confronting Racism in Chemistry Journals. ACS Infectious Diseases, 2020, 6, 1529-1531.	1.8	0
190	Confronting Racism in Chemistry Journals. ACS Applied Bio Materials, 2020, 3, 3925-3927.	2.3	0
191	Confronting Racism in Chemistry Journals. Journal of Physical Chemistry C, 2020, 124, 14069-14071.	1.5	0
192	Confronting Racism in Chemistry Journals. ACS Macro Letters, 2020, 9, 1004-1006.	2.3	0
193	Confronting Racism in Chemistry Journals. Molecular Pharmaceutics, 2020, 17, 2229-2231.	2.3	1
194	Confronting Racism in Chemistry Journals. ACS Chemical Neuroscience, 2020, 11, 1852-1854.	1.7	1
195	Confronting Racism in Chemistry Journals. ACS Photonics, 2020, 7, 1586-1588.	3.2	0
196	Confronting Racism in Chemistry Journals. Environmental Science & Technology, 2020, 54, 7735-7737.	4.6	0
197	Confronting Racism in Chemistry Journals. Journal of Chemical Health and Safety, 2020, 27, 198-200.	1.1	0
198	NeuroChat with Professor Thomas E. Prisinzaro. ACS Chemical Neuroscience, 2020, 11, 3993-3994.	1.7	0

#	ARTICLE	IF	CITATIONS
199	FAREWELL. ACS Chemical Neuroscience, 2020, 11, 3995-3995.	1.7	0
200	NeuroChat with Dr. Abdul Mannan Baig. ACS Chemical Neuroscience, 2020, 11, 3174-3176.	1.7	1
201	NeuroChat with Dr. Paul A. Newhouse. ACS Chemical Neuroscience, 2020, 11, 2900-2902.	1.7	0
202	NeuroChat with Professor Clinton E. Canal. ACS Chemical Neuroscience, 2020, 11, 3485-3487.	1.7	0
203	Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M <sub>1</sub> Positive Allosteric Modulators. ACS Chemical Neuroscience, 2019, 10, 1035-1042.	1.7	5
204	NeuroChat with Professor Erin Calipari. ACS Chemical Neuroscience, 2019, 10, 2623-2624.	1.7	0
205	Evaluation of Synthetic Cytochrome P <sub>450</sub> -Mimetic Metalloporphyrins To Facilitate $\alpha$ Biomimetic $\beta$ -Biotransformation of a Series of mGlu <sub>5</sub> Allosteric Ligands. ACS Omega, 2019, 4, 12782-12789.	1.6	2
206	Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu <sub>3</sub> NAMs: Challenging SAR, enantiospecific activity and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2670-2674.	1.0	0
207	Acute Negative Allosteric Modulation of M <sub>5</sub> Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration and Cue-Induced Reactivity with No Effect on Antinociception. ACS Chemical Neuroscience, 2019, 10, 3740-3750.	1.7	27
208	Total synthesis of Punicagranine. Tetrahedron Letters, 2019, 60, 150989.	0.7	0
209	NeuroChat with Professor W. Michael Caudle. ACS Chemical Neuroscience, 2019, 10, 2625-2627.	1.7	0
210	The effect of the EP <sub>3</sub> antagonist DG-041 on male mice with diet-induced obesity. Prostaglandins and Other Lipid Mediators, 2019, 144, 106353.	1.0	11
211	NeuroChat with Professor Catherine Abbott. ACS Chemical Neuroscience, 2019, 10, 4185-4186.	1.7	0
212	NeuroChat with Professor Philippe Derreumaux. ACS Chemical Neuroscience, 2019, 10, 3334-3334.	1.7	0
213	NeuroChat with Professor Cody Wenthur. ACS Chemical Neuroscience, 2019, 10, 2085-2086.	1.7	0
214	Formal Total Synthesis of Pericoannosin A. Journal of Organic Chemistry, 2019, 84, 12187-12191.	1.7	2
215	Total synthesis of violaceimides A-E and consideration of the reported stereochemistry. Tetrahedron Letters, 2019, 60, 151103.	0.7	0
216	Discovery of a novel 3,4-dimethylcinnoline carboxamide M <sub>4</sub> positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126678.	1.0	7

#	ARTICLE	IF	CITATIONS
217	Editors'™ Favorites: Best of 2018. ACS Chemical Neuroscience, 2019, 10, 1-4.	1.7	0
218	Structure-Activity Relationships, Pharmacokinetics, and Pharmacodynamics of the Kir6.2/SUR1-Specific Channel Opener VU0071063. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 350-359.	1.3	13
219	SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2224-2228.	1.0	4
220	Identification of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Acting at Site Distinct from 2-Methyl-6-(phenylethynyl)-pyridine Binding. ACS Chemical Neuroscience, 2019, 10, 3427-3436.	1.7	5
221	NeuroChat with Professor Kathryn Commons. ACS Chemical Neuroscience, 2019, 10, 2084-2084.	1.7	0
222	mGlu <sub>5</sub> Positive Allosteric Modulators Facilitate Long-Term Potentiation via Disinhibition Mediated by mGlu <sub>5</sub> -Endocannabinoid Signaling. ACS Pharmacology and Translational Science, 2019, 2, 198-209.	2.5	19
223	VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1714-1718.	1.0	6
224	Asymmetric Synthesis of Natural and Unnatural Dibenzylbutane Lignans from a Common Intermediate. Journal of Organic Chemistry, 2019, 84, 5974-5979.	1.7	3
225	Towards a TREK-1/2 (TWIK-Related K <sup>+</sup> Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1601-1604.	1.0	5
226	Total Synthesis of Hinduchelins A-D, Stereochemical Revision of Hinduchelin A, and Biological Evaluation of Natural and Unnatural Analogues. Journal of Organic Chemistry, 2019, 84, 6459-6464.	1.7	4
227	Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections. ACS Chemical Neuroscience, 2019, 10, 1115-1115.	1.7	14
228	Call for Papers: Strategies and Tactics in CNS Drug Synthesis. ACS Chemical Neuroscience, 2019, 10, 1116-1116.	1.7	0
229	M1 Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder. Biological Psychiatry, 2019, 85, 989-1000.	0.7	25
230	Surveying heterocycles as amide bioisosteres within a series of mGlu7 NAMs: Discovery of VU6019278. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1211-1214.	1.0	14
231	Preparation of 1,5-Dihydropyrazolo[3,4-b]pyridines via a Microwave-Assisted, Palladium-Catalyzed Regioselective C-H Heteroarylation of Electron-Rich Pyrazoles. Journal of Organic Chemistry, 2019, 84, 5855-5862.	1.7	11
232	NeuroChat with Professor Danny Winder. ACS Chemical Neuroscience, 2019, 10, 4766-4767.	1.7	0
233	NeuroChat with Martin Paulus, M.D.. ACS Chemical Neuroscience, 2019, 10, 4183-4184.	1.7	0
234	Crystal structure of the M <sub>5</sub> muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26001-26007.	3.3	48

#	ARTICLE	IF	CITATIONS
235	<i>In Vitro</i> to <i>In Vivo</i> Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 442-452.	2.5	7
236	NeuroChat with Professor Corey R. Hopkins. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4442-4443.	1.7	0
237	Biased M <sub>1</sub> receptor <sup>+</sup> positive allosteric modulators reveal role of phospholipase D in M <sub>1</sub> -dependent rodent cortical plasticity. <i>Science Signaling</i> , 2019, 12, .	1.6	9
238	Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in $\beta^2$ -amino carboxamide-harboring ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 362-366.	1.0	4
239	Direct activation of G-protein-gated inward rectifying K <sup>+</sup> channels promotes nonrapid eye movement sleep. <i>Sleep</i> , 2019, 42, .	0.6	12
240	Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. <i>Platelets</i> , 2019, 30, 126-135.	1.1	27
241	Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 47-50.	1.0	5
242	Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu <sub>7</sub> Negative Allosteric Modulator (NAM) in Vivo Tool Compound: <i>N</i> -(2-(1 <i>H</i> -1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1690-1695.	2.9	20
243	Discovery of Novel Central Nervous System Penetrant Metabotropic Glutamate Receptor Subtype 2 (mGlu <sub>2</sub> ) Negative Allosteric Modulators (NAMs) Based on Functionalized Pyrazolo[1,5- <i>a</i> ]pyrimidine-5-carboxamide and Thieno[3,2- <i>b</i> ]pyridine-5-carboxamide Cores. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 378-384.	2.9	17
244	The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 342-346.	1.0	6
245	Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson <sup>™</sup> s Disease. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 255-260.	1.3	17
246	Mechanisms underlying prelimbic prefrontal cortex mGlu3/mGlu5-dependent plasticity and reversal learning deficits following acute stress. <i>Neuropharmacology</i> , 2019, 144, 19-28.	2.0	43
247	Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1294-1299.	1.7	15
248	Discovery, Structure <sup>+</sup> Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 <i>H</i> -Pyrazolo[4,3- <i>b</i> ]pyridin-3-yl)amino)-benzo[ <i>d</i> ]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu <sub>4</sub> ). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 342-358.	2.9	16
249	The Muscarinic Acetylcholine Receptor M <sub>5</sub> : Therapeutic Implications and Allosteric Modulation. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1025-1034.	1.7	21
250	Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function. <i>Molecular Psychiatry</i> , 2019, 24, 916-927.	4.1	41
251	Discovery and Optimization of Potent and CNS Penetrant M <sub>5</sub> -Preferring Positive Allosteric Modulators Derived from a Novel, Chiral <i>N</i> -(Indanyl)piperidine Amide Scaffold. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1572-1581.	1.7	13
252	Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1679-1685.	1.0	2



#	ARTICLE	IF	CITATIONS
253	Structure-Activity Relationships of Pan-G <sub>11</sub> Coupled Muscarinic Acetylcholine Receptor Positive Allosteric Modulators. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1818-1828.	1.7	7
254	PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2218-2224.	1.7	19
255	Genetic and Rare Disease of the CNS. Part II: Holoprosencephaly (HPE). <i>ACS Chemical Neuroscience</i> , 2018, 9, 626-627.	1.7	4
256	Muscarinic M5 receptors modulate ethanol seeking in rats. <i>Neuropsychopharmacology</i> , 2018, 43, 1510-1517.	2.8	33
257	Editors' Favorites of 2017. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1-4.	1.7	2
258	Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning. <i>Psychopharmacology</i> , 2018, 235, 815-827.	1.5	23
259	Contextual Fear Extinction Induces Hippocampal Metaplasticity Mediated by Metabotropic Glutamate Receptor 5. <i>Cerebral Cortex</i> , 2018, 28, 4291-4304.	1.6	17
260	A Novel M <sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2274-2285.	1.7	43
261	Classics in Chemical Neuroscience: Risperidone. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1520-1529.	1.7	60
262	Use of chemical probes to explore the toxicological potential of the K <sup>+</sup> /Cl <sup>-</sup> cotransporter (KCC) as a novel insecticide target to control the primary vector of dengue and Zika virus, <i>Aedes aegypti</i> . <i>Pesticide Biochemistry and Physiology</i> , 2018, 151, 10-17.	1.6	9
263	mGlu1 and mGlu5 modulate distinct excitatory inputs to the nucleus accumbens shell. <i>Neuropsychopharmacology</i> , 2018, 43, 2075-2082.	2.8	27
264	M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. <i>Neuropsychopharmacology</i> , 2018, 43, 1763-1771.	2.8	56
265	Differential Pharmacology and Binding of mGlu <sub>2</sub> Receptor Allosteric Modulators. <i>Molecular Pharmacology</i> , 2018, 93, 526-540.	1.0	27
266	Call for Papers: Allosteric Modulators of Drug Targets—Special Issue for 2019. <i>ACS Chemical Neuroscience</i> , 2018, 9, 391-391.	1.7	0
267	Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M <sub>4</sub> Muscarinic Receptor as a Novel Therapeutic Target. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 291-300.	1.3	29
268	Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. <i>Neuropharmacology</i> , 2018, 128, 492-502.	2.0	35
269	Selective inhibition of M <sub>5</sub> muscarinic acetylcholine receptors attenuates cocaine self-administration in rats. <i>Addiction Biology</i> , 2018, 23, 1106-1116.	1.4	29
270	Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system. <i>Neuropharmacology</i> , 2018, 128, 301-313.	2.0	79



#	ARTICLE	IF	CITATIONS
271	Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 387.	1.4	33
272	Sterol 14 $\alpha$ -Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10910-10921.	2.9	18
273	Beyond the Amyloid Hypothesis of Alzheimer's Disease: Tau Pathology Takes Center Stage. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2519-2519.	1.7	8
274	Isoform selective PLD inhibition by novel, chiral 2,8-diazaspiro[4.5]decan-1-one derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3670-3673.	1.0	12
275	DARK Classics in Chemical Neuroscience: Opium, a Historical Perspective. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2503-2518.	1.7	41
276	Welcome to the DARK Side: DARK Classics in Chemical Neuroscience. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2286-2286.	1.7	0
277	What Papers Are People Citing and What Are People Reading?. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2097-2098.	1.7	0
278	VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 917-922.	1.3	11
279	Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor. <i>Biochemical Pharmacology</i> , 2018, 154, 243-254.	2.0	19
280	DARK Classics in Chemical Neuroscience: Phencyclidine (PCP). <i>ACS Chemical Neuroscience</i> , 2018, 9, 2459-2474.	1.7	31
281	Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2641-2646.	1.0	9
282	The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2175-2179.	1.0	10
283	2018: A New Impact Factor and an Expanded Cast of Associate Editors. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1517-1517.	1.7	0
284	New 2017 Data and Statistics for Pharmaceutical Products. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1518-1519.	1.7	8
285	Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. , 2018, 59, 446.		35
286	Sterol 14 $\alpha$ -Demethylase Structure-Based Design of VNI Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5679-5691.	2.9	35
287	Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. <i>Molecular Pharmacology</i> , 2018, 94, 926-937.	1.0	39
288	Development of novel inhibitors of swelling-activated LRRRC8 anion channels. <i>FASEB Journal</i> , 2018, 32, 567.3.	0.2	0

#	ARTICLE	IF	CITATIONS
289	Discovery, characterization, and preclinical development of a Kir4.1 ( KCNJ10 ) inhibitor for the treatment of hypertension. <i>FASEB Journal</i> , 2018, 32, 829.8.	0.2	0
290	Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1062-1069.	1.0	7
291	Classics in Chemical Neuroscience: Xanomeline. <i>ACS Chemical Neuroscience</i> , 2017, 8, 435-443.	1.7	39
292	One pot synthesis of unsymmetrical ketones from carboxylic and boronic acids via PyClU-mediated acylative Suzuki coupling. <i>Tetrahedron Letters</i> , 2017, 58, 898-901.	0.7	8
293	Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5- <i>d</i> ]pyrimidine-2,4(1 <i>H</i> ),3 <i>H</i> )-dione <sup>10</sup> Core. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1611-1616.	2.9	10
294	Editors' Favorites of 2016. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1-3.	1.7	1
295	Disease-Modifying Effects of M <sub>1</sub> Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1177-1187.	1.7	36
296	Targeting phospholipase D in cancer, infection and neurodegenerative disorders. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 351-367.	21.5	161
297	Unresponsive Choline Transporter as a Trait Neuromarker and a Causal Mediator of Bottom-Up Attentional Biases. <i>Journal of Neuroscience</i> , 2017, 37, 2947-2959.	1.7	34
298	Continued optimization of the M <sub>5</sub> NAM ML375: Discovery of VU6008667, an M <sub>5</sub> NAM with high CNS penetration and a desired short half-life in rat for addiction studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1356-1359.	1.0	23
299	The Ecstasy and Agony of Assay Interference Compounds. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2165-2168.	2.9	113
300	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Central Science</i> , 2017, 3, 143-147.	5.3	78
301	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Chemical Neuroscience</i> , 2017, 8, 420-423.	1.7	8
302	The Ecstasy and Agony of Assay Interference Compounds. <i>Biochemistry</i> , 2017, 56, 1363-1366.	1.2	8
303	The Ecstasy and Agony of Assay Interference Compounds. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 387-390.	2.5	20
304	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 379-382.	1.3	35
305	Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. <i>Assay and Drug Development Technologies</i> , 2017, 15, 113-119.	0.6	30
306	Optimization of M <sub>4</sub> positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2296-2301.	1.0	17

#	ARTICLE	IF	CITATIONS
307	Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2479-2483.	1.0	2
308	Return of D <sub>4</sub> Dopamine Receptor Antagonists in Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7233-7243.	2.9	40
309	Challenges in the development of an M <sub>4</sub> PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidone-derived amides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2990-2995.	1.0	16
310	Total Synthesis and Biological Evaluation of Hybrubin A. <i>Journal of Organic Chemistry</i> , 2017, 82, 431-437.	1.7	8
311	novel, CNS penetrant pan-muscarinic antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3576-3581.	1.0	10
312	Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5072-5085.	2.9	26
313	The Ecstasy and Agony of Assay Interference Compounds. <i>ACS Infectious Diseases</i> , 2017, 3, 259-262.	1.8	4
314	M <sub>1</sub> muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. <i>Neuropharmacology</i> , 2017, 118, 209-222.	2.0	32
315	Diverse Effects on M <sub>1</sub> Signaling and Adverse Effect Liability within a Series of M <sub>1</sub> Ago-PAMs. <i>ACS Chemical Neuroscience</i> , 2017, 8, 866-883.	1.7	44
316	Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIb/IIIa Activation in Human Platelets. <i>Molecular Pharmacology</i> , 2017, 91, 39-47.	1.0	29
317	Discovery of VU0467485/AZ13713945: An M <sub>4</sub> PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 233-238.	1.3	43
318	Challenges in the development of an M <sub>4</sub> PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 171-175.	1.0	32
319	Discoidin domain receptor 1 kinase activity is required for regulating collagen IV synthesis. <i>Matrix Biology</i> , 2017, 57-58, 258-271.	1.5	38
320	Preparation of Unsymmetrical 1,2,4,5-Tetrazines via a Mild Suzuki Cross-Coupling Reaction. <i>Organic Letters</i> , 2017, 19, 5693-5696.	2.4	27
321	Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M <sub>4</sub> positive allosteric modulator (PAM) chemotype via scaffold hopping. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4999-5001.	1.0	15
322	Species-Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu <sub>5</sub> -Negative Allosteric Modulator VU0424238 (Auglurant). <i>Drug Metabolism and Disposition</i> , 2017, 45, 1245-1259.	1.7	22
323	Emerging Data Strengthens the Argument That the Microbiome Is the Fifth Horseman of the Drug Discovery Apocalypse. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1813-1813.	1.7	1
324	ACS Chemical Neuroscience: Most Cited Papers from 2016. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2097-2098.	1.7	0

#	ARTICLE	IF	CITATIONS
325	Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidone-derived tertiary amides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5179-5184.	1.0	17
326	<i>ACS Chemical Neuroscience</i> : Most Cited Papers from 2015. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1633-1634.	1.7	0
327	Chronic Traumatic Encephalopathy (CTE): A Brief Historical Overview and Recent Focus on NFL Players. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1629-1631.	1.7	14
328	Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4274-4279.	1.0	8
329	Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4858-4866.	1.0	8
330	Discovery of VU6005649, a CNS Penetrant mGlu <sub>7/8</sub> Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1110-1115.	1.3	28
331	Is the Microbiome the Fifth Horseman of the Apocalypse in Drug Discovery? Implications for the Gut-Brain Axis. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1430-1430.	1.7	2
332	Classics in Chemical Neuroscience: Memantine. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1823-1829.	1.7	55
333	Development and kilogram-scale synthesis of mGlu5 negative allosteric modulator VU0424238 (auglurant). <i>Tetrahedron Letters</i> , 2017, 58, 3554-3558.	0.7	3
334	Design and Synthesis of <i>N</i> -Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu <sub>3</sub> NAMs. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 925-930.	1.3	38
335	mGlu <sub>7</sub> potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	55
336	Design and Synthesis of mGlu <sub>2</sub> NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 919-924.	1.3	33
337	New 2016 Data and Statistics for Global Pharmaceutical Products and Projections through 2017. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1635-1636.	1.7	44
338	Feeling Rejected? <i>ACS Chemical Neuroscience</i> Can Help Get Your Science to the Neuroscience Community As Quickly As Possible. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2348-2348.	1.7	0
339	Embarking on a 5 Year Journey to Highlight Genetic and Rare Diseases of the Central Nervous System. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2349-2349.	1.7	3
340	Call for Papers: <i>DARK</i> Classics in Chemical Neuroscience. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1812-1812.	1.7	3
341	VU6010608, a Novel mGlu <sub>7</sub> NAM from a Series of <i>N</i> -(2-(1 <i>H</i> -1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1326-1330.	1.3	18
342	Role of mGlu <sub>5</sub> Receptors and Inhibitory Neurotransmission in M <sub>1</sub> Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2254-2265.	1.7	21

#	ARTICLE	IF	CITATIONS
343	Reflections on 2016 and Projecting Forward. ACS Chemical Neuroscience, 2017, 8, 1117-1117.	1.7	0
344	Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology, 2017, 42, 2553-2566.	2.8	15
345	Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron, 2017, 96, 1358-1372.e4.	3.8	43
346	Genetic and Rare Disease of the CNS. Part I: Fatal Familial Insomnia (FFI). ACS Chemical Neuroscience, 2017, 8, 2570-2572.	1.7	3
347	A Possible Repeal of the Orphan Drug Tax Credit?. ACS Chemical Neuroscience, 2017, 8, 2569-2569.	1.7	0
348	Torn from the Headlines: <i>Angiostrongylus cantonensis</i> (Rat Lungworm) Is Established in Florida. ACS Chemical Neuroscience, 2017, 8, 1632-1632.	1.7	1
349	cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition. Oncotarget, 2017, 8, 101072-101086.	0.8	6
350	A Call to Action on Mental Illness from the World Health Organization. ACS Chemical Neuroscience, 2016, 7, 1620-1621.	1.7	2
351	01â€04â€05: Selective Potentiation Of Muscarinic Acetylcholine Receptor Subtype 1 Demonstrates Efficacy And Safety In Preclinical Models Of Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P181.	0.4	0
352	Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2481-2488.	1.0	18
353	Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2915-2919.	1.0	3
354	Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3822-3825.	1.0	11
355	Evaluating the Disposition of a Mixed Aldehyde Oxidase/Cytochrome P450 Substrate in Rats with Attenuated P450 Activity. Drug Metabolism and Disposition, 2016, 44, 1296-1303.	1.7	15
356	Total synthesis of actinophenanthroline A. Tetrahedron Letters, 2016, 57, 2194-2196.	0.7	7
357	Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4). ACS Chemical Neuroscience, 2016, 7, 1192-1200.	1.7	39
358	Re-exploration of the mGlu1 PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2289-2292.	1.0	7
359	Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3029-3033.	1.0	22
360	ROMK inhibitor actions in the nephron probed with diuretics. American Journal of Physiology - Renal Physiology, 2016, 310, F732-F737.	1.3	13

#	ARTICLE	IF	CITATIONS
361	Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1543-1551.	1.7	9
362	Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1 <i>H</i> -indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against $\beta$ -Thrombin. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7690-7695.	2.9	13
363	Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4282-4286.	1.0	11
364	Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4487-4491.	1.0	15
365	Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4637-4640.	1.0	3
366	Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. <i>Neuron</i> , 2016, 91, 1244-1252.	3.8	110
367	Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M <sub>1</sub> PAM VU6004256. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1706-1716.	1.7	39
368	2015: A New Impact Factor for <i>ACS Chemical Neuroscience</i> and New Topline Data for Global Pharmaceutical Products. <i>ACS Chemical Neuroscience</i> , 2016, 7, 842-843.	1.7	9
369	Total Synthesis of Combamide A. <i>Organic Letters</i> , 2016, 18, 3810-3813.	2.4	13
370	Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu <sub>2/4</sub> Heteromers. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1201-1211.	1.7	50
371	PhRMA: Placing Prescription Drugs into Context. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1312-1312.	1.7	1
372	Discovery, characterization and biological evaluation of a novel (R)-4,4-difluoropiperidine scaffold as dopamine receptor 4 (D4R) antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5757-5764.	1.0	12
373	Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5481-5486.	1.0	11
374	Anatomical localization of Ca <sub>v</sub> 3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys. <i>Journal of Neurophysiology</i> , 2016, 115, 470-485.	0.9	23
375	Discovery and characterization of a novel series of N-phenylsulfonyl-1 <i>H</i> -pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu <sub>4</sub> ). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2984-2987.	1.0	5
376	N-Alkylpyrido[1,2-a:2',1'-b]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu <sub>1/5</sub> with CNS exposure in rodents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1894-1900.	1.0	9
377	Lead optimization of the VU0486321 series of mGlu <sub>1</sub> PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1869-1872.	1.0	10
378	Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. <i>Chemical Reviews</i> , 2016, 116, 6707-6741.	23.0	151



#	ARTICLE	IF	CITATIONS
379	Lead optimization of the VU0486321 series of mGlu 1 PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 751-756.	1.0	15
380	mGlu <sub>5</sub> positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1990-2004.	1.4	48
381	An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. <i>Neuropsychopharmacology</i> , 2016, 41, 2052-2061.	2.8	60
382	Preliminary investigation of 6,7-dihydropyrazolo[1,5- a ]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 429-434.	1.0	7
383	State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects. <i>Neuropharmacology</i> , 2016, 102, 244-253.	2.0	23
384	Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair. <i>Journal of Biomolecular Screening</i> , 2016, 21, 74-87.	2.6	2
385	Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. <i>Neuropsychopharmacology</i> , 2016, 41, 1166-1178.	2.8	33
386	Discovery of VU0409551/JNJ-46778212: An mGlu <sub>5</sub> Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 716-720.	1.3	41
387	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. <i>Cell</i> , 2015, 161, 1252-1265.	13.5	135
388	Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2720-2725.	1.0	10
389	Development and Validation of a Thallium Flux-Based Functional Assay for the Sodium Channel NaV1.7 and Its Utility for Lead Discovery and Compound Profiling. <i>ACS Chemical Neuroscience</i> , 2015, 6, 871-878.	1.7	22
390	A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1718-1726.	1.7	9
391	VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 356, 123-136.	1.3	41
392	Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14078-14083.	3.3	41
393	A general, enantioselective synthesis of N-alkyl terminal aziridines and C2-functionalized azetidines via organocatalysis. <i>Tetrahedron Letters</i> , 2015, 56, 1276-1279.	0.7	17
394	Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1310-1317.	1.0	9
395	Identification and Characterization of ML352: A Novel, Noncompetitive Inhibitor of the Presynaptic Choline Transporter. <i>ACS Chemical Neuroscience</i> , 2015, 6, 417-427.	1.7	21
396	Human Phospholipase D Activity Transiently Regulates Pyrimidine Biosynthesis in Malignant Gliomas. <i>ACS Chemical Biology</i> , 2015, 10, 1258-1268.	1.6	20

#	ARTICLE	IF	CITATIONS
397	A Rodent Model of Traumatic Stress Induces Lasting Sleep and Quantitative Electroencephalographic Disturbances. <i>ACS Chemical Neuroscience</i> , 2015, 6, 485-493.	1.7	45
398	Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1196-1201.	3.3	86
399	Further optimization of the M5 NAM MLPCN probe ML375: Tactics and challenges. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 690-694.	1.0	20
400	Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles. <i>Neuropsychopharmacology</i> , 2015, 40, 755-765.	2.8	40
401	Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1757-1760.	1.0	4
402	Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3515-3519.	1.0	7
403	Microplate-Based Assay for Identifying Small Molecules That Bind a Specific Intersubunit Interface within the Assembled HIV-1 Capsid. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5190-5195.	1.4	3
404	2014 Prescription Medications in the United States: Tremendous Growth, Specialty/Orphan Drug Expansion, and Dispensed Prescriptions Continue to Increase. <i>ACS Chemical Neuroscience</i> , 2015, 6, 811-812.	1.7	8
405	Phospholipase D1 Couples CD4+ T Cell Activation to c-Myc-Dependent Deoxyribonucleotide Pool Expansion and HIV-1 Replication. <i>PLoS Pathogens</i> , 2015, 11, e1004864.	2.1	36
406	Effects of VU0410120, a novel GlyT1 inhibitor, on measures of sociability, cognition and stereotypic behaviors in a mouse model of autism. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 61, 10-17.	2.5	18
407	Activation of Metabotropic Glutamate Receptor 7 Is Required for Induction of Long-Term Potentiation at SC-CA1 Synapses in the Hippocampus. <i>Journal of Neuroscience</i> , 2015, 35, 7600-7615.	1.7	40
408	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. <i>Neuropharmacology</i> , 2015, 95, 121-129.	2.0	46
409	Biased mGlu 5 -Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents. <i>Neuron</i> , 2015, 86, 1029-1040.	3.8	121
410	Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. <i>Biochemical Pharmacology</i> , 2015, 98, 167-181.	2.0	43
411	Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9027-9040.	2.9	31
412	Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). <i>Journal of Biomolecular Screening</i> , 2015, 20, 858-868.	2.6	25
413	Competition and allosterism govern substrate selectivity of cyclooxygenase-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12366-12371.	3.3	24
414	Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu <sub>1</sub> ), Based on an N-(3-Chloro-4-(1,3-dioxoisindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu <sub>1</sub> Receptors Found in Schizophrenics. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7959-7971.	2.9	17



#	ARTICLE	IF	CITATIONS
415	Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5115-5120.	1.0	5
416	Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A <sub>2</sub> Activity and Its Role in Human Platelet Activation. <i>Biochemistry</i> , 2015, 54, 5578-5588.	1.2	14
417	Optimization of a small molecule probe that restores e-cadherin expression. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4260-4264.	1.0	4
418	Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7485-7500.	2.9	62
419	Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5107-5110.	1.0	12
420	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. <i>Neuron</i> , 2015, 88, 762-773.	3.8	183
421	Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-Dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 384-388.	1.0	9
422	Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. <i>Oncotarget</i> , 2015, 6, 22934-22948.	0.8	11
423	Selective Antagonism of mGlu5 Alters Sleep-wake and Spectral EEG and Ameliorates Behavioral Abnormalities in a Rodent Model of Traumatic Stress. <i>FASEB Journal</i> , 2015, 29, 615.8.	0.2	1
424	A Novel Approach to Cholinergic Signaling Modulation: Development and Characterization of ML352, a Novel, Noncompetitive Inhibitor of the Presynaptic Choline Transporter. <i>FASEB Journal</i> , 2015, 29, 932.6.	0.2	0
425	M <sub>5</sub> Receptor Activation Produces Opposing Physiological Outcomes in Dopamine Neurons Depending on the Receptor's Location. <i>Journal of Neuroscience</i> , 2014, 34, 3253-3262.	1.7	64
426	Phospholipase D Facilitates Efficient Entry of Influenza Virus, Allowing Escape from Innate Immune Inhibition. <i>Journal of Biological Chemistry</i> , 2014, 289, 25405-25417.	1.6	52
427	Discovery of		

#	ARTICLE	IF	CITATIONS
433	Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function. <i>Neurochemistry International</i> , 2014, 73, 113-121.	1.9	15
434	Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1062-1066.	1.0	6
435	A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors. <i>Journal of Biomolecular Screening</i> , 2014, 19, 847-858.	2.6	12
436	Synthesis and SAR of substituted pyrazolo[1,5-a]quinazolines as dual mGlu2/mGlu3 NAMs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2693-2698.	1.0	24
437	Drugs for Allosteric Sites on Receptors. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 165-184.	4.2	218
438	Chemical modulation of glycerolipid signaling and metabolic pathways. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 1060-1084.	1.2	27
439	Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1067-1070.	1.0	8
440	Classics in Chemical Neuroscience: Fluoxetine (Prozac). <i>ACS Chemical Neuroscience</i> , 2014, 5, 14-23.	1.7	71
441	Discovery, Synthesis and Characterization of a Highly Muscarinic Acetylcholine Receptor (mAChR)-selective M <sub>5</sub> -orthosteric Antagonist, VU0488130 (ML381): A Novel Molecular Probe. <i>ChemMedChem</i> , 2014, 9, 1677-1682.	1.6	25
442	Specific Activin Receptor-Like Kinase 3 Inhibitors Enhance Liver Regeneration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 549-558.	1.3	24
443	Pharmacoeconomics and the Medicinal Chemist. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1066-1068.	1.3	6
444	Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor within VivoActivity. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1060-1064.	1.3	16
445	Discovery of potent and selective GIRK1/2 modulators via "molecular switches"™ within a series of 1-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)ureas. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5102-5106.	1.0	15
446	Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4708-4713.	1.0	35
447	Chemical Modulation of Mutant mGlu <sub>1</sub> Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics. <i>ACS Chemical Biology</i> , 2014, 9, 2334-2346.	1.6	46
448	Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 692-708.	21.5	226
449	A Novel Class of Succinimide-Derived Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Provides Insight into a Disconnect in Activity between the Rat and Human Receptors. <i>ACS Chemical Neuroscience</i> , 2014, 5, 597-610.	1.7	45
450	2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug Discovery Targeting Allosteric Sites. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7485-7498.	2.9	28

#	ARTICLE	IF	CITATIONS
451	Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer. <i>Pharmacological Reviews</i> , 2014, 66, 1033-1079.	7.1	209
452	Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100. <i>Neuropsychopharmacology</i> , 2014, 39, 1578-1593.	2.8	91
453	Tetrahydronaphthyridine and Dihydronaphthyridinone Ethers As Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 5 (mGlu <sub>5</sub> ). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5620-5637.	2.9	13
454	Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3307-3314.	1.0	9
455	Development of a Highly Potent, Novel M <sub>5</sub> Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1 <i>H</i> -Indazol-5-yl)sulfonyl)- <i>N</i> -ethyl- <i>N</i> -(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7804-7810.	2.9	28
456	Selective Activation of M <sub>4</sub> Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents. <i>ACS Chemical Neuroscience</i> , 2014, 5, 920-942.	1.7	116
457	M4 mAChR-Mediated Modulation of Glutamatergic Transmission at Corticostriatal Synapses. <i>ACS Chemical Neuroscience</i> , 2014, 5, 318-324.	1.7	84
458	Identification of Specific Ligand-Receptor Interactions That Govern Binding and Cooperativity of Diverse Modulators to a Common Metabotropic Glutamate Receptor 5 Allosteric Site. <i>ACS Chemical Neuroscience</i> , 2014, 5, 282-295.	1.7	48
459	A Unique Industrial Academic Collaboration Towards the Next Generation of Schizophrenia Therapeutics. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 304-312.	1.0	9
460	Octahydropyrrolo[3,4- <i>c</i> ]pyrrole negative allosteric modulators of mGlu1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5091-5096.	1.0	9
461	Classics in Chemical Neuroscience: Clozapine. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1018-1025.	1.7	111
462	Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5779-5785.	1.0	30
463	Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. <i>Drug Discovery Today</i> , 2013, 18, 1185-1199.	3.2	107
464	Further exploration of M1 allosteric agonists: Subtle structural changes abolish M1 allosteric agonism and result in pan-mAChR orthosteric antagonism. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 223-227.	1.0	8
465	Discovery of the First M <sub>5</sub> -Selective and CNS Penetrant Negative Allosteric Modulator (NAM) of a Muscarinic Acetylcholine Receptor: (<i>S</i>)-9 <i>b</i> -(4-Chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1 <i>H</i> -imidazo[2,1- <i>a</i> ]isoindol-5(9 <i>b</i> - <i>H</i> )-one (ML375). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9351-9355.	2.9	62
466	Discovery and SAR of a novel series of GIRK1/2 and GIRK1/4 activators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5195-5198.	1.0	22
467	Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: The continued optimization of an MLPCN probe molecule. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1860-1864.	1.0	28
468	Dihydrothiazolopyridone Derivatives as a Novel Family of Positive Allosteric Modulators of the Metabotropic Glutamate 5 (mGlu <sub>5</sub> ) Receptor. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7243-7259.	2.9	20

#	ARTICLE	IF	CITATIONS
469	Total Synthesis of Stemaphylline Oxide and Related C9 Epimeric Analogues. <i>Chemistry - A European Journal</i> , 2013, 19, 11847-11852.	1.7	22
470	A general, enantioselective synthesis of 1-azabicyclo[m.n.0]alkane ring systems. <i>Tetrahedron Letters</i> , 2013, 54, 1645-1648.	0.7	23
471	Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 346-350.	1.0	37
472	N-Acyl-N <sup>2</sup> -arylpiperazines as negative allosteric modulators of mGlu1: Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3713-3718.	1.0	14
473	Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity. <i>Biological Psychiatry</i> , 2013, 73, 501-509.	0.7	95
474	Discovery of ML326: The first sub-micromolar, selective M5 PAM. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2996-3000.	1.0	21
475	Discovery of $\epsilon$ -molecular switches <sup>TM</sup> within a GIRK activator scaffold that afford selective GIRK inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4562-4566.	1.0	26
476	Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1. <i>Neuropharmacology</i> , 2013, 66, 170-178.	2.0	45
477	Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e269-e276.	4.0	38
478	ML297 (VU0456810), the First Potent and Selective Activator of the GIRK Potassium Channel, Displays Antiepileptic Properties in Mice. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1278-1286.	1.7	135
479	Discovery of (R)-(-2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl)(3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu <sub>3</sub> Selective and CNS Penetrant Negative Allosteric Modulator (NAM). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5208-5212.	2.9	52
480	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of Dorsomorphin: The discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3248-3252.	1.0	69
481	Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: Continued optimization of an MLPCN probe molecule. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 412-416.	1.0	20
482	Towards the Total Synthesis of Marineosin A: Construction of the Macrocyclic Pyrrole and an Advanced, Functionalized Spiroaminal Model. <i>European Journal of Organic Chemistry</i> , 2013, 2013, 4215-4218.	1.2	23
483	Exploration of Allosteric Agonism Structure-Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu <sub>5</sub> ) Positive Allosteric Modulators (PAMs): Discovery of 5-((3-Fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7976-7996.	2.9	28
484	Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012). <i>Pharmaceutical Patent Analyst</i> , 2013, 2, 93-108.	0.4	25
485	Substituted 1-Phenyl-3-(pyridin-2-yl)urea Negative Allosteric Modulators of mGlu <sub>5</sub> : Discovery of a New Tool Compound VU0463841 with Activity in Rat Models of Cocaine Addiction. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1217-1228.	1.7	16
486	Probing the Metabotropic Glutamate Receptor 5 (mGlu <sub>5</sub> ) Positive Allosteric Modulator (PAM) Binding Pocket: Discovery of Point Mutations That Engender a $\epsilon$ -Molecular Switch in PAM Pharmacology. <i>Molecular Pharmacology</i> , 2013, 83, 991-1006.	1.0	70

#	ARTICLE	IF	CITATIONS
487	Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1703-1714.	1.7	42
488	Allosteric Modulators for the Treatment of Schizophrenia: Targeting Glutamatergic Networks. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 26-54.	1.0	74
489	Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets. <i>PLoS ONE</i> , 2013, 8, e65528.	1.1	27
490	Novel Positive Allosteric Modulators Bias Acetylcholine Signaling at Human M4 Muscarinic Receptors. <i>FASEB Journal</i> , 2013, 27, 1171.4.	0.2	0
491	Effects of M1 and M4 muscarinic acetylcholine receptor positive allosteric modulators on sleep and cognition in rodents. <i>FASEB Journal</i> , 2013, 27, 661.8.	0.2	0
492	The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with L-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 404-421.	1.3	95
493	Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity, Affinity, and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships. <i>Molecular Pharmacology</i> , 2012, 82, 860-875.	1.0	90
494	Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses That Correspond with Behavioral Effects in Animal Models. <i>Journal of Neuroscience</i> , 2012, 32, 8532-8544.	1.7	98
495	Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1445-1464.	2.9	212
496	Chemical Modification of the M <sub>1</sub> Agonist VU0364572 Reveals Molecular Switches in Pharmacology and a Bitopic Binding Mode. <i>ACS Chemical Neuroscience</i> , 2012, 3, 1025-1036.	1.7	29
497	Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators. <i>Journal of Molecular Modeling</i> , 2012, 18, 4437-4446.	0.8	9
498	Discovery and SAR of a novel series of non-MPEP site mGlu5 PAMs based on an aryl glycine sulfonamide scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7388-7392.	1.0	16
499	Metabotropic glutamate receptor 4 (mGlu <sub>4</sub> )-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 461-481.	2.4	35
500	Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function. <i>Molecular Pharmacology</i> , 2012, 81, 120-133.	1.0	112
501	Biomimetic Synthesis and Biological Evaluation of Aplidiopsamine A. <i>Organic Letters</i> , 2012, 14, 5808-5810.	2.4	26
502	Total Synthesis and Biological Evaluation of Phidianidines A and B Uncovers Unique Pharmacological Profiles at CNS Targets. <i>ACS Chemical Neuroscience</i> , 2012, 3, 658-664.	1.7	39
503	Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicotinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic (M4) receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5084-5088.	1.0	39
504	Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: Development of a highly selective and more potent in vitro probe. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4532-4535.	1.0	78

#	ARTICLE	IF	CITATIONS
505	Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5035-5040.	1.0	13
506	Alzheimer's Disease: Development of Disease-Modifying Treatments Is the Challenge for Our Generation. <i>ACS Chemical Neuroscience</i> , 2012, 3, 804-805.	1.7	15
507	Optimization of an ether series of mGlu5 positive allosteric modulators: Molecular determinants of MPEP-site interaction crossover. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6481-6485.	1.0	9
508	Synthesis and biological characterization of a series of novel diaryl amide M1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6923-6928.	1.0	7
509	The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1834-1845.	1.7	36
510	Roles of the M1 Muscarinic Acetylcholine Receptor Subtype in the Regulation of Basal Ganglia Function and Implications for the Treatment of Parkinson's Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 595-603.	1.3	64
511	A General, Enantioselective Synthesis of Protected Morpholines and Piperazines. <i>Organic Letters</i> , 2012, 14, 2910-2913.	2.4	30
512	Targeting Selective Activation of M <sub>1</sub> for the Treatment of Alzheimer's Disease: Further Chemical Optimization and Pharmacological Characterization of the M <sub>1</sub> Positive Allosteric Modulator ML169. <i>ACS Chemical Neuroscience</i> , 2012, 3, 884-895.	1.7	41
513	A Versatile Enantioselective Synthesis of Azabicyclic Ring Systems: A Concise Total Synthesis of (+)-Grandisine-D and Unnatural Analogues. <i>Chemistry - A European Journal</i> , 2012, 18, 5826-5831.	1.7	33
514	Discovery of 2-(2-Benzoxazolyl amino)-4-Aryl-5-Cyanopyrimidine as Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptor <sub>5</sub> (mGlu <sub>5</sub> ): From an Artificial Neural Network Virtual Screen to an In Vivo Tool Compound. <i>ChemMedChem</i> , 2012, 7, 406-414.	1.6	38
515	Phospholipase D as a Therapeutic Target in Brain Disorders. <i>Neuropsychopharmacology</i> , 2012, 37, 301-302.	2.8	21
516	Contribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice. <i>Psychopharmacology</i> , 2012, 220, 673-685.	1.5	35
517	Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1044-1048.	1.0	6
518	Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3467-3472.	1.0	17
519	Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3921-3925.	1.0	33
520	Enantioselective synthesis of C2-functionalized, N-protected morpholines and orthogonally N,N <sup>2</sup> -protected piperazines via organocatalysis. <i>Tetrahedron Letters</i> , 2012, 53, 1539-1542.	0.7	15
521	Synthesis and biological evaluation of cremastrine and an unnatural analogue. <i>Tetrahedron Letters</i> , 2012, 53, 3577-3580.	0.7	20
522	Discovery of an inward rectifying potassium channel inhibitor with preference for Kir2.3, Kir3.X and Kir7.1. <i>FASEB Journal</i> , 2012, 26, 695.14.	0.2	0



#	ARTICLE	IF	CITATIONS
523	Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 1309-1338.	2.4	55
524	(3-Cyano-5-fluorophenyl)biaryl Negative Allosteric Modulators of mGlu <sub>5</sub> : Discovery of a New Tool Compound with Activity in the OSS Mouse Model of Addiction. <i>ACS Chemical Neuroscience</i> , 2011, 2, 471-482.	1.7	23
525	Discovery, Synthesis, and Structure-Activity Relationship Development of a Series of <i>N</i> -(4-Acetamido)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 (mGlu <sub>4</sub> ) with CNS Exposure in Rats. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1106-1110.	2.9	45
526	Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS Therapeutics. <i>ACS Chemical Neuroscience</i> , 2011, 2, 433-449.	1.7	34
527	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2011, 2, 730-742.	1.7	80
528	Total Synthesis of (+)-7-Bromotrypargine and Unnatural Analogues: Biological Evaluation Uncovers Activity at CNS Targets of Therapeutic Relevance. <i>ACS Chemical Neuroscience</i> , 2011, 2, 633-639.	1.7	17
529	Discovery, Synthesis, and Structure-Activity Relationship Development of a Series of <i>N</i> -(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu <sub>4</sub> ) with Oral Efficacy in an Antiparkinsonian Animal Model. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7639-7647.	2.9	52
530	Molecular Switches on mGluR Allosteric Ligands That Modulate Modes of Pharmacology. <i>Biochemistry</i> , 2011, 50, 2403-2410.	1.2	155
531	Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6451-6455.	1.0	32
532	Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu <sub>4</sub> ) antagonist: Unexpected molecular switch from a closely related mGlu <sub>4</sub> positive allosteric modulator. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6955-6959.	1.0	16
533	The synthesis and preclinical evaluation in rhesus monkey of [ <sup>18</sup> F]MK6577 and [ <sup>11</sup> C]CMPyPB glycine transporter 1 positron emission tomography radiotracers. <i>Synapse</i> , 2011, 65, 261-270.	0.6	35
534	Discovery of molecular switches within the ADX-47273 mGlu <sub>5</sub> PAM scaffold that modulate modes of pharmacology to afford potent mGlu <sub>5</sub> NAMs, PAMs and partial antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2711-2714.	1.0	41
535	Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2697-2701.	1.0	63
536	Synthesis and SAR of centrally active mGlu <sub>5</sub> positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1350-1353.	1.0	37
537	Discovery of a Novel Chemical Class of mGlu <sub>5</sub> Allosteric Ligands with Distinct Modes of Pharmacology. <i>ACS Chemical Neuroscience</i> , 2010, 1, 702-716.	1.7	70
538	Discovery of <i>N</i> -Aryl Piperazines as Selective mGlu <sub>5</sub> Potentiators with Improved In Vivo Utility. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 433-438.	1.3	35
539	Progress towards the synthesis of piperazimycin A: synthesis of the non-proteogenic amino acids and elaboration into dipeptides. <i>Tetrahedron Letters</i> , 2010, 51, 2493-2496.	0.7	11
540	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 558-562.	1.0	43

#	ARTICLE	IF	CITATIONS
541	Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M1 positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 531-536.	1.0	48
542	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1972-1975.	1.0	51
543	Synthesis and SAR of N-(4-(4-alkylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2174-2177.	1.0	8
544	3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu5: Identification of easily prepared tool compounds with CNS exposure in rats. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4390-4394.	1.0	20
545	Total synthesis and biological evaluation of tambjamine K and a library of unnatural analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5207-5211.	1.0	31
546	Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5175-5178.	1.0	26
547	Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5617-5622.	1.0	29
548	The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation: A 2009 Update. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 458-477.	1.0	98
549	Attenuation of Cocaine's Reinforcing and Discriminative Stimulus Effects via Muscarinic M <sub>1</sub> Acetylcholine Receptor Stimulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 959-969.	1.3	44
550	Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity. <i>Molecular Pharmacology</i> , 2010, 78, 1105-1123.	1.0	176
551	<i>In Vivo</i> Structure-Activity Relationship Study of Dorsomorphin Analogues Identifies Selective VEGF and BMP Inhibitors. <i>ACS Chemical Biology</i> , 2010, 5, 245-253.	1.6	361
552	Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening. <i>ACS Chemical Neuroscience</i> , 2010, 1, 288-305.	1.7	42
553	Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. <i>ACS Chemical Neuroscience</i> , 2010, 1, 411-419.	1.7	45
554	Design, Synthesis, and Biological Evaluation of Halogenated N-(2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: Discovery of an Isoform-Selective Small Molecule Phospholipase D2 Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6706-6719.	2.9	92
555	Differential Effects of Allosteric M <sub>1</sub> Muscarinic Acetylcholine Receptor Agonists on Receptor Activation, Arrestin 3 Recruitment, and Receptor Downregulation. <i>ACS Chemical Neuroscience</i> , 2010, 1, 542-551.	1.7	22
556	Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M <sub>1</sub> Receptor Function in the Central Nervous System. <i>ACS Chemical Neuroscience</i> , 2010, 1, 104-121.	1.7	88
557	Evaluation of the Biosynthetic Proposal for the Synthesis of Marineosins A and B. <i>Organic Letters</i> , 2010, 12, 1048-1051.	2.4	37
558	The antipsychotic potential of muscarinic allosteric modulation. <i>Drug News and Perspectives</i> , 2010, 23, 229.	1.9	53



#	ARTICLE	IF	CITATIONS
559	Discovery and Characterization of Novel Allosteric Potentiators of M <sub>1</sub> Muscarinic Receptors Reveals Multiple Modes of Activity. <i>Molecular Pharmacology</i> , 2009, 75, 577-588.	1.0	135
560	Selective activation of the M <sub>1</sub> muscarinic acetylcholine receptor achieved by allosteric potentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15950-15955.	3.3	253
561	mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning. <i>Neuropsychopharmacology</i> , 2009, 34, 2057-2071.	2.8	199
562	Discovery and Development of a Potent and Highly Selective Small Molecule Muscarinic Acetylcholine Receptor Subtype 1 (mAChR 1 or M1) Antagonist In Vitro and In Vivo Probe. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1217-1226.	1.0	14
563	mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. <i>Future Medicinal Chemistry</i> , 2009, 1, 501-513.	1.1	59
564	A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 Antagonist Reduces Seizures without Impairing Hippocampus-Dependent Learning. <i>Molecular Pharmacology</i> , 2009, 76, 356-368.	1.0	121
565	A Selective Allosteric Potentiator of the M <sub>1</sub> Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning. <i>Journal of Neuroscience</i> , 2009, 29, 14271-14286.	1.7	217
566	Synthesis, SAR and Unanticipated Pharmacological Profiles of Analogues of the mGluR5 Ago-potentiator ADX-47273. <i>ChemMedChem</i> , 2009, 4, 505-511.	1.6	36
567	Synthesis and Structure-Activity Relationships of Allosteric Potentiators of the M <sub>4</sub> Muscarinic Acetylcholine Receptor. <i>ChemMedChem</i> , 2009, 4, 1600-1607.	1.6	35
568	MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines. <i>Tetrahedron Letters</i> , 2009, 50, 212-215.	0.7	17
569	Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 41-54.	21.5	929
570	Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1916-1920.	1.0	101
571	A novel class of H3 antagonists derived from the natural product guided synthesis of unnatural analogs of the marine bromopyrrole alkaloid dispyrin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3204-3208.	1.0	18
572	Total synthesis of Eudistomins Y1-Y6. <i>Tetrahedron Letters</i> , 2009, 50, 7067-7069.	0.7	15
573	Discovery of N-[[1-(propylsulfonyl)-4-pyridin-2-yl]piperidin-4-yl]methyl]benzamides as novel, selective and potent GlyT1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1488-1491.	1.0	23
574	Discovery of GlyT1 inhibitors with improved pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1492-1495.	1.0	23
575	Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2240-2243.	1.0	63
576	Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3209-3213.	1.0	34

#	ARTICLE	IF	CITATIONS
577	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6623-6626.	1.0	18
578	Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6502-6506.	1.0	18
579	Discovery of Molecular Switches That Modulate Modes of Metabotropic Glutamate Receptor Subtype 5 (mGlu <sub>5</sub> ) Pharmacology in Vitro and in Vivo within a Series of Functionalized, Regioisomeric 2- and 5-(Phenylethynyl)pyrimidines. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4103-4106.	2.9	72
580	Synthesis and Evaluation of a Series of Heterobiaryl amides That Are Centrally Penetrant Metabotropic Glutamate Receptor 4 (mGluR4) Positive Allosteric Modulators (PAMs). <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4115-4118.	2.9	79
581	Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy <i>N</i> -Benzyl Isatins. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3445-3448.	2.9	92
582	Rapid, General Access to Chiral $\hat{I}^2$ -Fluoroamines and $\hat{I}^2, \hat{I}^2$ -Difluoroamines via Organocatalysis. <i>Organic Letters</i> , 2009, 11, 943-946.	2.4	93
583	Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 25-31.	4.0	325
584	Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 148-155.	4.0	258
585	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 225-225.	1.0	4
586	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 416-417.	1.0	19
587	Modulation of Synaptic Transmission by G Protein $\hat{I}^2, \hat{I}^3$ Subunits. <i>FASEB Journal</i> , 2009, 23, 583.2.	0.2	0
588	A Small Molecule Screen Identifies Novel Inhibitors of the Neuronal $\text{K}^+\text{Cl}^-$ cotransporter KCC2. <i>FASEB Journal</i> , 2009, 23, 797.6.	0.2	0
589	Insulin regulation of dopamine transporter activity.. <i>FASEB Journal</i> , 2009, 23, .	0.2	1
590	Discovery and Characterization of a Novel Subtype-selective M1 Allosteric Agonist for the Treatment of Alzheimer's Disease. <i>FASEB Journal</i> , 2009, 23, 756.12.	0.2	0
591	Recent progress in the discovery and development of negative allosteric modulators of mGluR5. <i>Current Opinion in Drug Discovery &amp; Development</i> , 2009, 12, 446-57.	1.9	31
592	Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 949-63.	1.0	21
593	Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 885-890.	1.0	18
594	Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4098-4101.	1.0	80

#	ARTICLE	IF	CITATIONS
595	A new multi-gram synthetic route to labeling precursors for the D2/3 PET agent 18F-fallypride. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4467-4469.	1.0	4
596	Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5439-5442.	1.0	37
597	Allosteric modulation of kinases and GPCRs: design principles and structural diversity. <i>Current Opinion in Chemical Biology</i> , 2008, 12, 269-280.	2.8	80
598	Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureasâ€”The effect of capping the distal basic piperidine nitrogen. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5443-5447.	1.0	29
599	Application of Combinatorial Chemistry Science on Modern Drug Discovery. <i>ACS Combinatorial Science</i> , 2008, 10, 345-354.	3.3	206
600	Total Synthesis and Biological Evaluation of the Marine Bromopyrrole Alkaloid Dispyrin: Elucidation of Discrete Molecular Targets with Therapeutic Potential. <i>Journal of Natural Products</i> , 2008, 71, 1783-1786.	1.5	26
601	A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies. <i>Nuclear Medicine and Biology</i> , 2008, 35, 315-325.	0.3	25
602	G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms. <i>ACS Chemical Biology</i> , 2008, 3, 530-541.	1.6	154
603	Total Synthesis of Ciliatamides A-C: Stereochemical Revision and the Natural Product-Guided Synthesis of Unnatural Analogs. <i>Organic Letters</i> , 2008, 10, 4545-4548.	2.4	14
604	Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4. <i>Molecular Pharmacology</i> , 2008, 74, 1345-1358.	1.0	187
605	Novel Selective Allosteric Activator of the M <sub>1</sub> Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats. <i>Journal of Neuroscience</i> , 2008, 28, 10422-10433.	1.7	219
606	The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors. <i>Current Cancer Drug Targets</i> , 2008, 8, 7-18.	0.8	84
607	Centrally Active Allosteric Potentiators of the M <sub>4</sub> Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 941-953.	1.3	177
608	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 434-434.	1.0	1
609	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1158-1158.	1.0	0
610	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1553-1553.	1.0	2
611	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1100-1100.	1.0	3
612	Schizophrenia: Moving Beyond Monoamine Antagonists. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2008, 8, 99-107.	3.4	82

#	ARTICLE	IF	CITATIONS
613	Characterization of novel selective positive allosteric modulators (PAMS) of the M4 muscarinic acetylcholine receptor (mAChR). <i>FASEB Journal</i> , 2008, 22, 714.2.	0.2	0
614	Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. <i>Current Opinion in Molecular Therapeutics</i> , 2008, 10, 591-601.	2.8	18
615	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1330-1330.	1.0	0
616	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 739-739.	1.0	4
617	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1248-1248.	1.0	0
618	Preclinical Drug Discovery Research and Training at Vanderbilt. <i>ACS Chemical Biology</i> , 2007, 2, 17-20.	1.6	7
619	Challenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1386-1391.	1.0	68
620	Convenient and General Microwave-Assisted Protocols for the Expedient Synthesis of Heterocycles. <i>Heterocycles</i> , 2006, 70, 655.	0.4	40
621	Design, Synthesis, and In Vivo Efficacy of Glycine Transporter-1 (GlyT1) Inhibitors Derived from a Series of [4-Phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl Benzamides. <i>ChemMedChem</i> , 2006, 1, 807-811.	1.6	43
622	Progress Towards Validating the NMDA Receptor Hypofunction Hypothesis of Schizophrenia. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 771-785.	1.0	140
623	Progress in the Preparation and Testing of Glycine Transporter Type-1 (GlyT1) Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1883-1896.	1.0	44
624	Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 761-764.	1.0	479
625	Discovery of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 (mGluR5). <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 825-846.	1.0	38
626	A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 199-206.	1.3	289
627	Accelerating lead development by microwave-enhanced medicinal chemistry. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 155-161.	4.0	53
628	A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 568-577.	1.3	175
629	Efficient Synthesis of Imidazoles from Aldehydes and 1,2-Diketones Using Microwave Irradiation. <i>Organic Letters</i> , 2004, 6, 1453-1456.	2.4	382
630	Discovery of Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 5 from a Series of N-(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides That Potentiate Receptor Function in Vivo. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5825-5828.	2.9	164

#	ARTICLE	IF	CITATIONS
631	Development of a Custom High-Throughput Preparative Liquid Chromatography/Mass Spectrometer Platform for the Preparative Purification and Analytical Analysis of Compound Libraries. ACS Combinatorial Science, 2003, 5, 322-329.	3.3	80
632	A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5. Molecular Pharmacology, 2003, 64, 731-740.	1.0	226
633	mGlu <sub>2</sub> and mGlu <sub>3</sub> Negative Allosteric Modulators Divergently Potentiate Thalamocortical Transmission and Exert Rapid Antidepressant-Like Effects. SSRN Electronic Journal, 0, , .	0.4	3